Klin Farmakol Farm. 2015;29(1):22-24

How will diabetes treatment change with new pharmaceuticals?

Milan Kvapil
Interní klinika FN v Motole a 2. LF UK, Praha

Type 2 diabetes mellitus is a heterogeneous disease, with the existing means failing to reach target values of compensation inall patients.

Therefore, completely new options for treating hyperglycaemia are beingsought andfound (SGLT2 inhibitors, gliptins, GLP-1 receptor

agonists). These newpharmaceuticals are at least as effective asolder typesof antidiabetic drugs, but they are certainly safer. Theirkey

propertyis minimal riskof hypoglycaemia. They gradually expand the pharmacotherapyoptions for type 2 diabetes andallow for individual

selection and adjustmentof treatment.

agonists, liraglutide, exenatide, lixisenatide.

Keywords: type 2 diabetes mellitus, gliflozins, SGLT2 inhibitors, gliptins, DPP-4 inhibitors, glycated haemoglobin HbA1c, GLP-1 receptor

Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. How will diabetes treatment change with new pharmaceuticals? Klin Farmakol Farm. 2015;29(1):22-24.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Washburn WN. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents. Expert Opin Ther Pat. 2012; 22(5): 483-494. Go to original source... Go to PubMed...
    2. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3-9. Go to original source... Go to PubMed...
    3. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol 2001; 280: F10-F18. Go to original source... Go to PubMed...
    4. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44(4): 375-393. Go to original source... Go to PubMed...
    5. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9): 2015-2022. Go to original source... Go to PubMed...
    6. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012; 32(1): 80-94. Go to original source... Go to PubMed...
    7. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156(6): 405-415. Go to original source... Go to PubMed...
    8. De Meester I, et al. Natural substrate of dipeptydyl petpidase IV. Adv Exp Med Biol, 2000; 477: 67-87. Go to original source... Go to PubMed...
    9. Ahrén B. Gut peptides and Type 2 diabetes mellitus treatment. Curr. Diab. Rep., 2003; 3: 365-372. Go to original source... Go to PubMed...
    10. Al Sifri S, et 2010 Ramadan Study Group: The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011; 65(11): 1132-1140. Go to original source... Go to PubMed...
    11. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011; 27(5): 1049-1058. Go to original source... Go to PubMed...
    12. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012; 14: 1061-1072. Go to original source... Go to PubMed...
    13. Furukawa S, Kumagi T, Miyake T, et al. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature. Endocr J. 2012; 59(4): 329-333. Go to original source... Go to PubMed...
    14. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012; 9(2): 109-116. Go to original source... Go to PubMed...
    15. Harashima SI, Ogura M, Tanaka D, et al. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract. 2012; 66(5): 465-476. Go to original source... Go to PubMed...
    16. Hollander P, Raslova K, Skj?th TV, et al. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab. 2011; 13(3): 268-275. Go to original source... Go to PubMed...
    17. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012; 14(9): 795-802. Go to original source... Go to PubMed...
    18. Kvapil M. Léčba kombinací bazálního inzulinu a inkretinové terapie. Diabetologie 2013, Triton, Praha.
    19. Lim S, An JH, Shin H, Khang AR, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf). 2012; 77(2): 215-223. Go to original source... Go to PubMed...
    20. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011; 27(Suppl 3): 57-64. Go to original source... Go to PubMed...
    21. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012; 29(1): 14-25. Go to original source... Go to PubMed...
    22. Öz Ö, K?y?c? S, Ersoy C, et al. Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes. Diabetes Res Clin Pract. 2011; 94(2): 212-216. Go to original source... Go to PubMed...
    23. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012; 46(11): 1453-1469. Go to original source... Go to PubMed...
    24. Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011; 13(7): 644-652. Go to original source... Go to PubMed...
    25. Rizos EC, Ntzani EE, Papanas N, et al. Combination Therapies of DPP4 Inhibitors and GLP1 Analogues with Insulin in Type 2 Diabetic Patients: A Systematic Review. Curr Vasc Pharmacol. 2012 Jun 22, PubMed PMID: 22724475.
    26. Seck TL, Engel SS, Williams-Herman DE, et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Res Clin Pract. 2011; 93(1): e15-7. Go to original source... Go to PubMed...
    27. Seck T, Nauck M, Sheng D, et al. Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010; 64(5): 562-576. Go to original source... Go to PubMed...
    28. Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2011; 59(6): 1148-1149. Go to original source... Go to PubMed...
    29. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010; 164: 58-64. Go to original source... Go to PubMed...
    30. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. Diabetes Care 2012; 35: 1225-1231. Go to original source... Go to PubMed...
    31. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience 2012, 13: 33. Go to original source... Go to PubMed...
    32. D'Alessio DA, Vahl TP. Glucagon-like peptid 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab., 2004; 286: E882-E890. Go to original source... Go to PubMed...
    33. Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568. Drugs R D. 2004; 5(1): 35-40. Go to original source... Go to PubMed...
    34. Exendin 4: AC 2993, AC 2993 LAR. BioDrugs. 2002; 16(3): 220-222. Go to original source... Go to PubMed...
    35. DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011; 13(11): 1145. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.